Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690872 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL496858 | 0.89 | GRM8 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL4959221 | 0.89 | GRM8 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Hydrochloric Acid SCHEMBL10636419 | 0.87 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3411544 | 0.86 | BLM (0.57) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29240009 | 0.86 | BLM (0.57) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL435290 | 0.85 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2917215 | 0.85 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL14125401 | 0.83 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL690870 | 0.83 | ALOX15 (0.39) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101119-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMA (US) | 2025-03-27 | — | — | US | claimed |
| US-12139546-B2 | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| US-20240041807-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2024-02-08 | — | — | US | claimed |
| US-11819483-B2 | Combination therapy to treat urea cycle disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-21 | — | — | US | claimed |
| US-20230181504-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2023-06-15 | — | — | US | claimed |
| US-20210130480-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMACEUTICALS, INC. | 2021-05-06 | — | — | US | claimed |
| EP-3672620-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | Regeneron Pharmaceuticals, Inc. (US) | 2020-07-01 | — | — | EP | claimed |
| US-20200170984-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2020-06-04 | — | — | US | claimed |
| EP-3645053-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | Baylor College of Medicine (US) | 2020-05-06 | — | — | EP | claimed |
| WO-2019040471-A9 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | claimed |
| WO-2019040471-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMACEUTICALS, INC. (US) | 2019-02-28 | — | — | WO | claimed |
| WO-2019006164-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2019-01-03 | — | — | WO | claimed |
| US-12414986-B2 | Use of glutamine synthetase for treating fatty liver disease | THOERIS GMBH (AT) | 2025-09-16 | — | — | US | disclosed |
| US-12359184-B2 | Use of glutamine synthetase for treating hyperammonemia | THOERIS GMBH (AT) | 2025-07-15 | — | — | US | disclosed |
| US-12338471-B2 | Use of glutamine synthetase for treating hyperammonemia | THOERIS GMBH (AT) | 2025-06-24 | — | — | US | disclosed |
| US-20250101119-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMA (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2019040471-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMACEUTICALS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019006164-A1 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018215780-A1 | USE OF GLUTAMINE SYNTHETASE FOR TREATING HYPERAMMONEMIA | Ammun Limited (GB) | 2018-11-29 | — | — | WO | disclosed |
| CN-105533207-A | Functional feed and mixed batch for alleviating heat stress of breeding boars | BEIJING RESOURCE ASIA-PACIFIC FEED TECH CO LTD | 2016-05-04 | — | — | CN | disclosed |